mesna and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

mesna has been researched along with Leukemia--Myelogenous--Chronic--BCR-ABL-Positive* in 2 studies

Other Studies

2 other study(ies) available for mesna and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

Article	Year
Massive pleural effusion attributed to high-dose cyclophosphamide during conditioning for BMT. Bone marrow transplantation, 1996, Volume: 18, Issue:1 A 37-year-old male developed massive pleural effusion leading to respiratory failure and electromechanical dissociation within 24 h after the second dose of 4200 mg cyclophosphamide (CY) during conditioning for allogeneic bone marrow transplantation for chronic myelogenous leukemia. After resuscitation and bilateral pleural drainage he recovered within 1 day. Subsequently, total body irradiation was given and with a delay of 1 day the transplantation procedure was continued without major complications. No explanation for this idiosyncratic reaction other than the administration of high dose CY in combination with mesna rescue was found. This reaction has not been reported before in the literature. Topics: Adult; Bone Marrow Transplantation; Cyclophosphamide; Drainage; Fluid Therapy; Heart Arrest; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mesna; Pleural Effusion; Respiratory Insufficiency; Transplantation Conditioning; Whole-Body Irradiation	1996
Haemorrhagic cystitis in bone marrow transplantation patients: possible increased risk associated with prior busulphan therapy. Bone marrow transplantation, 1987, Volume: 1, Issue:4 Following bone marrow transplantation employing conditioning including 'high-dose' cyclophosphamide, 65 patients were studied for the subsequent development of symptomatic haemorrhagic cystitis. There was no protection from the urothelial toxicity of cyclophosphamide metabolites afforded by the concurrent administration of 2-mercaptoethane sodium sulphonate (mesna) if timing errors in administration were made. Other factors which might increase the risk of haemorrhagic cystitis due to cyclophosphamide administration include the prior administration of busulphan to patients with chronic granulocytic leukaemia, in whom the incidence of haemorrhagic cystitis was 36% compared with 4% in all other patients. We have also investigated the use of intravesical prostaglandin E2 as a treatment for haemorrhagic cystitis in eight patients, two of whom appeared to obtain major benefit. Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cystitis; Female; Hematuria; Hemorrhage; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mesna; Middle Aged; Risk Factors	1987

Article

Year

Massive pleural effusion attributed to high-dose cyclophosphamide during conditioning for BMT.

Bone marrow transplantation, 1996, Volume: 18, Issue:1

A 37-year-old male developed massive pleural effusion leading to respiratory failure and electromechanical dissociation within 24 h after the second dose of 4200 mg cyclophosphamide (CY) during conditioning for allogeneic bone marrow transplantation for chronic myelogenous leukemia. After resuscitation and bilateral pleural drainage he recovered within 1 day. Subsequently, total body irradiation was given and with a delay of 1 day the transplantation procedure was continued without major complications. No explanation for this idiosyncratic reaction other than the administration of high dose CY in combination with mesna rescue was found. This reaction has not been reported before in the literature.

Topics: Adult; Bone Marrow Transplantation; Cyclophosphamide; Drainage; Fluid Therapy; Heart Arrest; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mesna; Pleural Effusion; Respiratory Insufficiency; Transplantation Conditioning; Whole-Body Irradiation

1996

Haemorrhagic cystitis in bone marrow transplantation patients: possible increased risk associated with prior busulphan therapy.

Bone marrow transplantation, 1987, Volume: 1, Issue:4

Following bone marrow transplantation employing conditioning including 'high-dose' cyclophosphamide, 65 patients were studied for the subsequent development of symptomatic haemorrhagic cystitis. There was no protection from the urothelial toxicity of cyclophosphamide metabolites afforded by the concurrent administration of 2-mercaptoethane sodium sulphonate (mesna) if timing errors in administration were made. Other factors which might increase the risk of haemorrhagic cystitis due to cyclophosphamide administration include the prior administration of busulphan to patients with chronic granulocytic leukaemia, in whom the incidence of haemorrhagic cystitis was 36% compared with 4% in all other patients. We have also investigated the use of intravesical prostaglandin E2 as a treatment for haemorrhagic cystitis in eight patients, two of whom appeared to obtain major benefit.

Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cystitis; Female; Hematuria; Hemorrhage; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mesna; Middle Aged; Risk Factors

1987